Abstract

Protocol Specific Research (PSR) provides support for development and conduct of short term pilot and early phase investigator-initiated clinical trials. PSR support is allocated for protocol development. Scientific Review Committee and IRB submission, data management, nursing support, and regulatory support. In addition, PSR support provides assurance that relevant investigator-initiated trials selected for funding have a full Data and Safety Monitoring Plan (DSMP), and that each trial receives internal quality assurance reviews. PSR services are available to all members of the Cancer Center. The first priority for utilization of PSR support services is given to investigator-initiated studies and NCI-sponsored trials.

Public Health Relevance

The PSR supports the development and conduct of clinical trials being carried out at the UC Davis Cancer Center. For example, the PSR ensures that each trial has an appropriate data and safety monitoring plan and undergoes quality assurance reviews.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA093373-12
Application #
8743655
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
12
Fiscal Year
2014
Total Cost
$105,013
Indirect Cost
$36,595

  Institution

Name
University of California Davis
Department
Type
DUNS #
047120084
City
Davis
State
CA
Country
United States
Zip Code
95618

  Publications

Wang, Minan; Yao, Li-Chin; Cheng, Mingshan et al. (2018) Humanized mice in studying efficacy and mechanisms of PD-1-targeted cancer immunotherapy. FASEB J 32:1537-1549
York, D; Sproul, C D; Chikere, N et al. (2018) Expression and targeting of transcription factor ATF5 in dog gliomas. Vet Comp Oncol 16:102-107
Fletcher, Kyle; Klosterman, Steven J; Derevnina, Lida et al. (2018) Comparative genomics of downy mildews reveals potential adaptations to biotrophy. BMC Genomics 19:851
Wang, Fuli; Zhang, Hongyong; Ma, Ai-Hong et al. (2018) COX-2/sEH Dual Inhibitor PTUPB Potentiates the Antitumor Efficacy of Cisplatin. Mol Cancer Ther 17:474-483
Yuan, Ye; He, Yixuan; Bo, Ruonan et al. (2018) A facile approach to fabricate self-assembled magnetic nanotheranostics for drug delivery and imaging. Nanoscale 10:21634-21639
Seo, Jai Woong; Tavaré, Richard; Mahakian, Lisa M et al. (2018) CD8+ T-Cell Density Imaging with 64Cu-Labeled Cys-Diabody Informs Immunotherapy Protocols. Clin Cancer Res 24:4976-4987
Xue, Xiangdong; Huang, Yee; Bo, Ruonan et al. (2018) Trojan Horse nanotheranostics with dual transformability and multifunctionality for highly effective cancer treatment. Nat Commun 9:3653
Knight, Jennifer F; Sung, Vanessa Y C; Kuzmin, Elena et al. (2018) KIBRA (WWC1) Is a Metastasis Suppressor Gene Affected by Chromosome 5q Loss in Triple-Negative Breast Cancer. Cell Rep 22:3191-3205
Couto, K M; Moore, P F; Zwingenberger, A L et al. (2018) Clinical characteristics and outcome in dogs with small cell T-cell intestinal lymphoma. Vet Comp Oncol 16:337-343
Dou, John; Schmidt, Rebecca J; Benke, Kelly S et al. (2018) Cord blood buffy coat DNA methylation is comparable to whole cord blood methylation. Epigenetics 13:108-116

Showing the most recent 10 out of 836 publications